Daiwa Securities Group
ELVN icon

Daiwa Securities Group’s Enliven Therapeutics ELVN Stock Holding History

Daiwa Securities Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-152
Closed -$2K – 1263
2025
Q4 		$2K Hold
152
– – ﹤0.01% 1302
2025
Q3 		$3K Hold
152
– – ﹤0.01% 1238
2025
Q2 		$3K Hold
152
– – ﹤0.01% 1189
2025
Q1 		$3K Hold
152
– – ﹤0.01% 1161
2024
Q4 		$3K Hold
152
– – ﹤0.01% 1190
2024
Q3 		$4K Hold
152
– – ﹤0.01% 1182
2024
Q2 		$4K Hold
152
– – ﹤0.01% 1212
2024
Q1 		$3K Buy
+152
New +$2.33K ﹤0.01% 1236

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Daiwa Securities Group's ELVN Position: Q1 2026 in Review

Daiwa Securities Group sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 152 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in ELVN in Q1 2024 and held it in 8 quarters. The position peaked at $4K in Q3 2024. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Daiwa Securities Group reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 152 Enliven Therapeutics shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in Enliven Therapeutics in Q1 2024 and held it in 8 quarters.
  • Daiwa Securities Group's Enliven Therapeutics position peaked at $4K in Q3 2024.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.